Marker Retained Earnings from 2010 to 2025

MRKR Stock

USD 1.19 0.09 7.03%

Marker Therapeutics Retained Earnings yearly trend continues to be relatively stable with very little volatility. Retained Earnings are likely to grow to about -373 M this year. Retained Earnings is the cumulative amount of net income that Marker Therapeutics retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. View All Fundamentals

Retained Earnings

First Reported

2000-03-31

Previous Quarter

-440.9 M

Current Value

-443.2 M

Quarterly Volatility

153.9 M

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check Marker Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Marker Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.6 M, Interest Expense of 12.9 K or Selling General Administrative of 5.6 M, as well as many indicators such as Price To Sales Ratio of 15.99, Dividend Yield of 0.0 or PTB Ratio of 3.26. Marker financial statements analysis is a perfect complement when working with Marker Therapeutics Valuation or Volatility modules.

Check out the analysis of Marker Therapeutics Correlation against competitors.

To learn how to invest in Marker Stock, please use our How to Invest in Marker Therapeutics guide.

Latest Marker Therapeutics' Retained Earnings Growth Pattern

Below is the plot of the Retained Earnings of Marker Therapeutics over the last few years. It is the cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. Marker Therapeutics' Retained Earnings historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Marker Therapeutics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported (436.29 M)

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Retained Earnings

Timeline

Marker Retained Earnings Regression Statistics

	Arithmetic Mean	(230,708,772)
	Geometric Mean	138,849,668
	Coefficient Of Variation	(69.03)
	Mean Deviation	146,542,891
	Median	(157,420,027)
	Standard Deviation	159,252,143
	Sample Variance	25361.2T
	Range	434.7M
	R-Value	(0.95)
	Mean Square Error	2427.7T
	R-Squared	0.91
	Slope	(31,920,411)
	Total Sum of Squares	380418.7T

Marker Retained Earnings History

	2025	-373 M
	2024	-392.7 M
	2023	-436.3 M
	2022	-428 M
	2021	-398.1 M
	2020	-356.2 M
	2019	-327.5 M

Other Fundumenentals of Marker Therapeutics

Retained Earnings Total Equity

Marker Therapeutics Retained Earnings component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Property Plant Equipment	Current Deferred Revenue	Net Tangible Assets	Capital Surpluse	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.92	-0.81	-0.71	0.69	0.17	0.36	0.95	-0.13	0.06	0.32	0.2	0.75	0.8	-0.66	0.94	0.85	0.25
Total Stockholder Equity	0.92		-0.88	-0.69	0.49	0.16	-0.02	0.94	-0.21	-0.13	0.31	0.18	0.85	0.78	-0.73	0.95	0.92	0.11
Net Debt	-0.81	-0.88		0.52	-0.32	0.1	0.02	-0.95	0.29	0.02	-0.09	0.05	-0.7	-0.63	0.56	-0.92	-0.97	-0.15
Retained Earnings	-0.71	-0.69	0.52		-0.42	-0.68	-0.25	-0.64	0.17	0.31	-0.8	-0.64	-0.91	-0.95	0.85	-0.64	-0.54	0.39
Accounts Payable	0.69	0.49	-0.32	-0.42		-0.04	0.62	0.51	0.31	0.43	0.33	0.23	0.33	0.42	-0.32	0.53	0.4	0.54
Net Receivables	0.17	0.16	0.1	-0.68	-0.04		0.15	0.03	-0.04	-0.43	0.74	0.74	0.54	0.56	-0.48	0.08	-0.05	-0.76
Total Liab	0.36	-0.02	0.02	-0.25	0.62	0.15		0.16	0.17	0.43	0.21	0.21	-0.04	0.19	0.01	0.16	0.02	0.31
Total Current Assets	0.95	0.94	-0.95	-0.64	0.51	0.03	0.16		-0.2	0.04	0.21	0.08	0.75	0.76	-0.63	0.97	0.96	0.21
Short Term Debt	-0.13	-0.21	0.29	0.17	0.31	-0.04	0.17	-0.2		0.79	0.05	0.43	-0.18	-0.22	0.32	-0.14	-0.18	0.11
Common Stock	0.06	-0.13	0.02	0.31	0.43	-0.43	0.43	0.04	0.79		-0.32	0.03	-0.34	-0.29	0.45	0.05	0.05	0.54
Property Plant Equipment	0.32	0.31	-0.09	-0.8	0.33	0.74	0.21	0.21	0.05	-0.32		0.7	0.7	0.66	-0.57	0.24	0.14	-0.55
Current Deferred Revenue	0.2	0.18	0.05	-0.64	0.23	0.74	0.21	0.08	0.43	0.03	0.7		0.53	0.53	-0.44	0.15	0.05	-0.57
Net Tangible Assets	0.75	0.85	-0.7	-0.91	0.33	0.54	-0.04	0.75	-0.18	-0.34	0.7	0.53		0.9	-0.84	0.78	0.73	-0.37
Capital Surpluse	0.8	0.78	-0.63	-0.95	0.42	0.56	0.19	0.76	-0.22	-0.29	0.66	0.53	0.9		-0.85	0.71	0.64	-0.27
Short Long Term Debt	-0.66	-0.73	0.56	0.85	-0.32	-0.48	0.01	-0.63	0.32	0.45	-0.57	-0.44	-0.84	-0.85		-0.6	-0.54	0.26
Net Invested Capital	0.94	0.95	-0.92	-0.64	0.53	0.08	0.16	0.97	-0.14	0.05	0.24	0.15	0.78	0.71	-0.6		0.97	0.18
Net Working Capital	0.85	0.92	-0.97	-0.54	0.4	-0.05	0.02	0.96	-0.18	0.05	0.14	0.05	0.73	0.64	-0.54	0.97		0.16
Capital Stock	0.25	0.11	-0.15	0.39	0.54	-0.76	0.31	0.21	0.11	0.54	-0.55	-0.57	-0.37	-0.27	0.26	0.18	0.16

Click cells to compare fundamentals

About Marker Therapeutics Financial Statements

Marker Therapeutics shareholders use historical fundamental indicators, such as Retained Earnings, to determine how well the company is positioned to perform in the future. Although Marker Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Marker Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Marker Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

	Last Reported	Projected for Next Year
Retained Earnings	-392.7 M	-373 M
Retained Earnings Total Equity	-320.6 M	-304.6 M

Additional Tools for Marker Stock Analysis

When running Marker Therapeutics' price analysis, check to measure Marker Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Marker Therapeutics is operating at the current time. Most of Marker Therapeutics' value examination focuses on studying past and present price action to predict the probability of Marker Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Marker Therapeutics' price. Additionally, you may evaluate how the addition of Marker Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC